Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 5, 2004, Pages 581-588

  Dillman, Robert ^a   Barth, Neil ^a   Selvan, Senthamil ^a   Beutel, Linda ^a   De Leon, Cristina ^a   DePriest, Carol ^a   Peterson, Cheryl ^a   Nayak, Shankar ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Delayed type hypersensitivity (DTH); Sarcoma; Tumor cell vaccines; Vaccine potency

Indexed keywords

AUTOLOGOUS CANCER VACCINE; CANCER VACCINE; GAMMIMMUNE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SARGAMOSTATIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOPRESERVATION; CYTOPENIA; DELAYED HYPERSENSITIVITY; DRUG SAFETY; EVALUATION; FEMALE; FEVER; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE; IRRADIATION; MALAISE; MALE; METASTASIS; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SARCOMA; SKIN INFECTION; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CRYOPRESERVATION; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SARCOMA; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 9144252310     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978042484812     Document Type: Article

References (20)

1. Borden EC, Baker LH, Bell RS, et al. Soft-tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003;9:1941.
2. Demetri GD, Delaney T, NCCN Sarcoma Practice Guidelines Panel. NCCN: Sarcoma. Cancer Control 2001;8(suppl. 2):94.
3. Maki RG. Immunity against soft-tissue sarcomas. Curr Oncol Rep 2003;5:282.
4. Lee SY, Obata Y, Yoshida M, et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 2003;100:2651.
5. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An interinstitute NIH study. Med Pediatr Oncol 2002;38:158.
6. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use inactive specific immunotherapy. J Immunother 1993;14:65.
7. Dillman RO, Nayak SK, Barth NM, et al. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 1998;13:165.
8. Dillman RO, Beutel LD, Cornforth AN, et al. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer Biother Radiopharm 2000; 15:161.
9. Dillman RO, de Leon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001;39:115.
10. Dillman RO, Barth NM, VanderMolen LA, et al. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm 2001;16:47.
11. Dillman RO, Beutel LD, Barth NM, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002;17:51.
12. Dillman RO, Wiemann M, Nayak SK, et al. Interferon-gamma or granulocyte macrophage colony stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase II trial of the Cancer Biotherapy Research Group. J Immunother 2003;26:367.
13. Karakousis CP, Perez RP. Soft-tissue sarcomas in adults. CA Cancer J Clin 1994;44:200.
14. Dillman RO, Crispin R, Oldham R. The Cancer Biotherapy Research Group [CBRG], (formerly(fon-nerly the National Biotherapy Study Group [NBSG]): A 10-year perspective. Cancer Biother Radiopharm 1997;12:229.
15. Schiltz PM, Nayak SH, Dillman RO. Dendritic cells derived from peripheral blood monocytes as autologous antigen presenting cells. [abstr. 3612]. Proc Am Assoc Cancer Research 1998;39:531.
16. Nayak SK, Schiltz PM, Dillman RO. Modulation of renal carcinoma cells in vitro: Comparison after transduction with retroviral vector containing a human γ-interferon gene versus incubation with γ-interferon protein. J Interferon Cytokine Res 1999;19:49.
17. Chang HR, Smelser S, Cardon-Cardo C, et al. Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft-tissue sarcomas. Cancer 1992;72:2956.
18. Selvan RS, Beatty A, Novak J, et al. Generation of cultured autologous tumor cells for tumor cell-pulsed dendritic cell vaccines in human metastatic melanoma and renal cell cancer. J Immunother 2002;25:S29.
19. Dillman RO, Selvan RS, Schiltz PM, et al. Early results with a vaccine of cultured autologous tumor cells and dendritic cells in metastatic melanoma and renal cell cancer. J Immunother 2002;25:S11.
20. Dillman R, Selvan S, Schiltz P, et al. Update on cultured autologous tumor cells and dendritic cells as patient-specific vaccines in recurrent or metastatic melanoma or renal cell cancer. J Immunother 2003;2:S5.